FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average b	ourden							
- 1	hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     REED VICKIE S				2. Issuer Name <b>and</b> Ticker or Trading Symbol Evoke Pharma Inc [ EVOK ]						(Cr	neck all applion	cable) or	Person(s) to Is	wner		
(Last) (First) (Middle) C/O EVOKE PHARMA, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/27/2022							below)	(give title	Other ( below)	specify	
420 STEVENS AVENUE, SUITE 370				If Amendment, Date of Original Filed (Month/Day/Year)												
(Street) SOLANA BEACH	A C	A	92075	4.	If Ame	ndment, I	Date	of Original Fi	iled (I	Month/Da	iy/Year)	Lin	e) <mark>X</mark> Form f	iled by One Riled by More	Filing (Check Ap Reporting Perso than One Repo	on
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		Code (In 8)	Transaction Code (Instr. 3, 5)  Disposed Of (D) (Instr. 3, 5)		tr. 3, 4 and	Benefici	es F ally (I Following (I	i. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V Amount (D)				1 1100	(Instr. 3						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	le of 2. 3. Transaction 3A. Deemed 4 Execution Date Execution Date, if any			5. Number of of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) Uni		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.66	04/27/2022		A		58,000		(1)	04	1/26/2032	Common Stock	58,000	\$0.00	58,000	D	

## **Explanation of Responses:**

1. The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date

## Remarks:

/s/ Matthew J. D'Onofrio,

Attorney-in-fact for Vickie S.

04/28/2022

Reed

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.